APA

Moreau P., Pylypenko H., Grosicki S., Karamanesht I., Leleu X., Grishunina M., Rekhtman G., Masliak Z., Robak T., Shubina A., Arnulf B., Kropff M., Cavet J., Esseltine D., Feng H., Girgis S., van de Velde H., Deraedt W. & Harousseau J. (20110628). Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. : The Lancet. Oncology.

Chicago

Moreau Philippe, Pylypenko Halyna, Grosicki Sebastian, Karamanesht Ievgenii, Leleu Xavier, Grishunina Maria, Rekhtman Grigoriy, Masliak Zvenyslava, Robak Tadeusz, Shubina Anna, Arnulf Bertrand, Kropff Martin, Cavet James, Esseltine Dixie-Lee, Feng Huaibao, Girgis Suzette, van de Velde Helgi, Deraedt William and Harousseau Jean-Luc. 20110628. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. : The Lancet. Oncology.

Harvard

Moreau P., Pylypenko H., Grosicki S., Karamanesht I., Leleu X., Grishunina M., Rekhtman G., Masliak Z., Robak T., Shubina A., Arnulf B., Kropff M., Cavet J., Esseltine D., Feng H., Girgis S., van de Velde H., Deraedt W. and Harousseau J. (20110628). Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. : The Lancet. Oncology.

MLA

Moreau Philippe, Pylypenko Halyna, Grosicki Sebastian, Karamanesht Ievgenii, Leleu Xavier, Grishunina Maria, Rekhtman Grigoriy, Masliak Zvenyslava, Robak Tadeusz, Shubina Anna, Arnulf Bertrand, Kropff Martin, Cavet James, Esseltine Dixie-Lee, Feng Huaibao, Girgis Suzette, van de Velde Helgi, Deraedt William and Harousseau Jean-Luc. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. : The Lancet. Oncology. 20110628.